http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1085885-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0f2ad6b4d4081ba2d8724466631ab640 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-66 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-66 |
| filingDate | 1999-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2a4c7461a50cd8a60e5e6c0eccdfe340 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_126928500c151b1cfdc7c73fb6676bdf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8736326d8be34f3ad558a78248700d47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ec1bc696bc8e014ef3334cbbadcd966b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3c75bad6df580b3ca6f8add46b727f9e |
| publicationDate | 2001-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-1085885-A2 |
| titleOfInvention | Method for assessing a diabetic's risk of experiencing a diabetes-associated pathologic condition |
| abstract | Disclosed is a class of compounds which inhibit the enzymatic conversion of fructose-lysine into fructose-lysine-3-phosphate in an ATP dependent reaction in a newly discovered metabolic pathway. According to the normal functioning on this pathway, fructose-lysine-3-phosphate (FL3P) is broken down to form free lysine, inorganic phosphate and 3-deoxyglucosone (3DG), the latter being a reactive protein modifying agent. 3DG can be detoxified by reduction to 3-deoxyfructose (3DF), or it can react with endogenous proteins to form advanced glycation end-product modified proteins (AGE-proteins), which are believed to be a contributing cause of diabetic complications. Also disclosed are therapeutic methods of using such inhibitors to reduce formation of AGE-proteins and thereby lessen, reduce and delay diabetic complications, as well as methods for assessing a diabetic's risk of developing complications and for determining the efficacy of the disclosed inhibitor therapy by measuring the ratio of 3DG to 3DF in a biological sample following an oral dose of a fructose-lysine-containing food product. |
| priorityDate | 1998-06-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 299.